Infliximab and pediatric stricturing Crohn's disease: a possible alternative to surgery? Experience of seven cases.

Introduction: Infliximab (IFX) is one of the treatments of choice for the different phenotypes of pediatric Crohn's disease (CD). Although it was initially feared that anti-TNFα treatment might cause bowel stenosis, recent studies have validated the efficacy of IFX as an anti-stricturing agent.

Aim: To assess the efficacy of IFX treatment for pediatric stricturing CD.

Features predicting unresectability in hepatoblastoma.

Background: Approximately 20% of patients who have hepatoblastoma (HB) still have unresectable disease after preoperative chemotherapy (POC). In these circumstances, orthotopic liver transplantation (OLT) should be performed 1 month after POC. The authors sought to identify presenting features that would predict unresectability in patients with HB and to provide suggestions for early referral and listing for OLT.